Treatment of Toxoplasmosis Gondii

Introduction to Treatment Guidelines

The American Academy of Pediatrics recommends the gold standard treatment for toxoplasmosis is pyrimethamine plus sulfadiazine plus leucovorin (folinic acid), with specific regimens varying based on whether the infection is congenital, acquired, or occurring in pregnancy 1, 2

For infants with confirmed or suspected congenital toxoplasmosis, the Centers for Disease Control and Prevention recommends treatment for 12 months with pyrimethamine, sulfadiazine, and leucovorin (folinic acid) 2, 3, 4
The American Academy of Pediatrics suggests that for CNS, ocular, or systemic toxoplasmosis in HIV-infected children, use acute therapy for 6 weeks with pyrimethamine, sulfadiazine, and leucovorin 1
For pregnant women with suspected or confirmed acute toxoplasmosis before 18 weeks gestation, the American College of Obstetricians and Gynecologists recommends initiating spiramycin immediately 5
At or after 18 weeks gestation, or if fetal infection is confirmed, the American College of Obstetricians and Gynecologists suggests switching to combination therapy with pyrimethamine, sulfadiazine, and folinic acid 2, 5, 6

The Centers for Disease Control and Prevention recommends performing complete blood counts at least weekly during daily pyrimethamine therapy and at least monthly during less-than-daily dosing to detect bone marrow suppression 1, 7
The American Academy of Pediatrics advises always administering leucovorin concurrently with pyrimethamine and continuing for 1 week after pyrimethamine discontinuation due to its long half-life 1, 7

The American Academy of Pediatrics warns never to rely on commercial laboratory IgM results alone for toxoplasmosis diagnosis—false positives are extremely common and lead to unnecessary interventions; always confirm at a reference laboratory 5
The American College of Obstetricians and Gynecologists cautions against delaying spiramycin initiation while awaiting confirmatory testing if acute toxoplasmosis is clinically suspected during pregnancy—early treatment significantly reduces transmission risk 5, 8
The Centers for Disease Control and Prevention advises never using pyrimethamine without leucovorin—this is the primary cause of severe bone marrow suppression 1, 9, 10, 7